Astatine-211--tellurium radiocolloid cures experimental malignant ascites.
An investigation of the efficacy of astatine-211--tellurium colloid for the treatment of experimental malignant ascites in mice reveals that this alpha-emitting radiocolloid can be curative without causing undue toxicity to normal tissue. By comparison, negatron-emitting phosphorus-32 as colloidal chromic phosphate had no antineoplastic activity. The most compelling explanation for this striking difference is the dense ionization and short range of action associated with alpha-emission. These results have important implications for the development and use of alpha-emitters as radiocolloid therapy for the treatment of human tumors.
D000512:Alpha Particles; D000818:Animals; D001201:Ascites / Q000532:radiotherapy*; D001246:Astatine / Q000627:therapeutic use*; D002470:Cell Survival / Q000528:radiation effects; D002857:Chromium / Q000627:therapeutic use; D017608:Chromium Compounds; D003102:Colloids; D005260:Female; D051379:Mice; D009368:Neoplasm Transplantation; D009374:Neoplasms, Experimental / Q000532:radiotherapy*; D010051:Ovarian Neoplasms; D010710:Phosphates / Q000627:therapeutic use; D010761:Phosphorus Radioisotopes / Q000627:therapeutic use; D011868:Radioisotopes / Q000627:therapeutic use*; D013691:Tellurium / Q000627:therapeutic use*; D014184:Transplantation, Homologous
D017608:Chromium Compounds; D003102:Colloids; D010710:Phosphates; D010761:Phosphorus Radioisotopes; D011868:Radioisotopes; D002857:Chromium; C509369:chromic phosphate; D013691:Tellurium; D001246:Astatine